Invetx specialises in developing protein-based therapeutics for chronic conditions in companion animals, with a focus on monoclonal antibodies (mAbs).
Dechra says these therapies have targeted modes of action and therefore are often more effective, provide an extended duration of activity and have fewer side effects, all of which help to extend and improve the quality of life for companion animals while decreasing the care burden for pet owners.
Jesper Nordengaard, Chief Executive Officer of Dechra, said: "I regard this acquisition as hugely important for Dechra, marking the start of a new chapter in our growth.
"It demonstrates our ambition to create further points of differentiation and relevance with veterinarians and pet owners alike, confidence in our ability to deliver highly innovative new products, and capacity to execute large scale transactions at speed."
Jesper added: “The half-life extension technology developed by Invetx allows for the generation of therapeutics that make treatment of chronic conditions far more convenient for pet owners and veterinarians through improved compliance.
"The pipeline of products currently being developed are all high value potential and will deepen our expertise in core therapeutic areas such as atopic dermatitis and osteoarthritis, allowing for synergistic product development, sales & marketing, and education efforts in the future.”
https://www.invetx.com
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.